tiprankstipranks
Trending News
More News >
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Australian Market
Advertisement

Vectus Biosystems Limited (VBS) AI Stock Analysis

Compare
5 Followers

Top Page

AU:VBS

Vectus Biosystems Limited

(Sydney:VBS)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
Vectus Biosystems Limited's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, persistent losses, and financial instability. While technical analysis shows some short-term positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves these areas unaddressed in the analysis.

Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)

Vectus Biosystems Limited Business Overview & Revenue Model

Company DescriptionVectus Biosystems Limited (VBS) is an Australian biotechnology company specializing in the development of novel treatments for fibrosis and high blood pressure. The company's core focus is on creating small molecule drugs aimed at treating fibrotic diseases, which are conditions characterized by the thickening and scarring of connective tissue. Vectus Biosystems is committed to addressing unmet medical needs through its innovative research and development efforts, and its leading product candidate is VB0004, which targets the fibrosis and hypertension markets.
How the Company Makes MoneyVectus Biosystems Limited generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company invests in extensive research and development to advance its product pipeline, with a key focus on VB0004. Revenue is expected to be derived from licensing agreements, partnerships with pharmaceutical companies, and potential sales of approved drugs. Strategic collaborations and partnerships play a significant role in funding Vectus' research initiatives and expanding its market reach. The company may also receive milestone payments and royalties from licensing its drug candidates to other entities as they progress through clinical trials and into commercialization.

Vectus Biosystems Limited Financial Statement Overview

Summary
Vectus Biosystems Limited is facing significant financial challenges, with declining revenues, persistent losses, and a weak balance sheet with negative equity. Cash flow issues further exacerbate the financial instability, indicating a need for strategic changes to improve financial health and sustainability.
Income Statement
20
Very Negative
Vectus Biosystems Limited has experienced a significant decline in revenue, with a revenue growth rate of -45.92% in the most recent year. The company has consistently reported negative net profit margins, indicating ongoing losses. Despite a high gross profit margin, the negative EBIT and EBITDA margins reflect operational inefficiencies and high costs relative to revenue.
Balance Sheet
15
Very Negative
The company's balance sheet shows a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is negative, reflecting more liabilities than equity. While the return on equity appears positive, it is due to negative equity, which is not a favorable sign. Overall, the balance sheet suggests financial distress and high leverage.
Cash Flow
25
Negative
Vectus Biosystems Limited has negative operating and free cash flows, indicating challenges in generating cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is less than one, suggesting inefficiencies in converting income into cash. The free cash flow to net income ratio is positive, but this is due to negative net income, which is not a positive indicator.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue478.18K478.18K1.14M1.35M1.30M180.00
Gross Profit478.18K478.18K1.14M1.31M1.28M1.02M
EBITDA-1.69M-1.69M-2.27M-3.19M-3.28M-3.71M
Net Income-1.78M-1.78M-2.34M-3.45M-3.99M-3.86M
Balance Sheet
Total Assets782.66K782.66K2.03M4.63M3.94M6.98M
Cash, Cash Equivalents and Short-Term Investments250.99K250.99K808.97K2.95M1.28M5.78M
Total Debt200.00K200.00K28.93K70.21K6.90M8.68M
Total Liabilities1.04M1.04M539.26K1.11M8.36M9.88M
Stockholders Equity-256.62K-256.62K1.49M3.52M-4.42M-2.90M
Cash Flow
Free Cash Flow-830.09K-830.09K-2.10M-2.37M-4.46M-3.26M
Operating Cash Flow-830.09K-830.09K-2.03M-2.35M-4.44M-3.26M
Investing Cash Flow101.03K101.03K-67.90K-17.13K-21.00K0.00
Financing Cash Flow171.07K171.07K-41.28K4.04M-34.55K6.35M

Vectus Biosystems Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.07
Price Trends
50DMA
0.07
Positive
100DMA
0.06
Positive
200DMA
0.07
Positive
Market Momentum
MACD
<0.01
Negative
RSI
54.38
Neutral
STOCH
-1.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of -1.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
AU$4.61M-628.72%31.87%
44
Neutral
AU$3.95M-289.05%24.09%
40
Underperform
AU$2.17M-28.49%46.43%
36
Underperform
$6.64M-184.73%87.88%
27
Underperform
AU$3.96M-205.70%1.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VBS
Vectus Biosystems Limited
0.07
-0.02
-22.22%
AU:BIT
Biotron
0.01
-0.01
-52.17%
AU:CMB
Regeneus Ltd.
0.46
0.01
2.22%
AU:1AD
AdAlta Ltd.
0.01
-0.01
-50.00%
AU:ANR
Anatara Lifesciences Ltd
0.02
-0.04
-66.67%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Advances Commercialization of Fibrosis Treatments
Jul 31, 2025

Vectus Biosystems Limited has made significant progress in its commercialization efforts, particularly with its lead compound VB0004, which targets fibrosis and high blood pressure. The company is actively engaged in licensing discussions and exploring opportunities for faster approval in the Chinese market. Vectus has also reduced its operating costs and is focusing on potential licensing and collaborations to fund further clinical studies. The company is working on obtaining a research and development cash-back claim to support its financial position.

Vectus Biosystems Expands Share Issuance Under Employee Incentive Plan
Jul 17, 2025

Vectus Biosystems Limited has issued 55,019 new fully paid ordinary shares to an employee under its Employee Incentive Plan. This move reflects the company’s ongoing efforts to incentivize its workforce and align employee interests with corporate goals, potentially impacting its operational dynamics and stakeholder relations.

Vectus Biosystems Expands Capital with New Securities Issuance
Jul 17, 2025

Vectus Biosystems Limited has announced the issuance of 55,019 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its financial flexibility and market presence positively.

Vectus Biosystems Issues Unquoted Options to Employees
Jun 27, 2025

Vectus Biosystems Limited announced the issuance of 75,000 unquoted options as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational dynamics and stakeholder relations positively.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025